Clinical trials: Glucose-6 Phosphate Dehydrogenase Deficiency
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Malaria
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with dihydroartemisinin-piperaquine in G6PD deficient males.
- Trial name
- SAFEPRIM-II (NCT02654730)
- Testing
- Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
- Where
- The Gambia
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Lapdap and Coartemether for Uncomplicated Malaria
Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap…
- Trial name
- NCT00118794
- Testing
- Chlorproguanil-dapsone (Lapdap), Lumefantrine-artemether (Coartemether )
- Where
- The Gambia
- Volunteers
- 1,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.
- Trial name
- NCT02389374
- Testing
- chloroquine, Artemether-lumefantrine combination, Primaquine
- Volunteers
- 181 people
- Sponsor
- Menzies School of Health Research
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Validation, Biosensors
Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative
This is a laboratory research to evaluate performances of quantitative POC G6PD tests (Biosensors) against gold standard quantitative laboratory based tests and genotyping.
- Conditions
- Validation, Biosensors, Genotyping
- Trial name
- Biosensors (NCT02625285)
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
G6PD Deficiency
Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise
The purpose of this study is to investigate the effects of N-acetyl Cystein (NAC) supplementation on redox status, physiological and biochemical parameters in G6PD deficient individuals after acute exercise.
- Trial name
- NCT02937376
- Testing
- N-acetyl cystein
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- University of Thessaly
G6PD Deficiency, Stroke
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention.
- Trial name
- SAST (NCT04088513)
- Testing
- Aspirin, Clopidogrel
- Where
- 19 sites in China
- Volunteers
- 440 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
G6PD Deficiency
Primaquine Enantiomers in G6PD Deficient Human Volunteers
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over…
- Trial name
- NCT04073953
- Testing
- RPQ, SPQ
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Mississippi, Oxford
Hyperbilirubinemia, Neonatal Indirect
The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia
This is a prospective, open-label, randomized controlled trial conducted at Lattakia University Hospital (Tishreen University), aiming to evaluate the efficacy of Ursodeoxycholic Acid (UDCA) as an adjuvant to triple phototherapy…
- Trial name
- UDCA-Neo (NCT07110987)
- Testing
- Phototherapy, ursodeoxycholic acid (UDCA)
- Where
- Syria
- Volunteers
- 70 people
- Sponsor
- Tishreen University Hospital
G6PD Deficiency
Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise
The purpose of this study is to investigate the effects of alpha-lipoic acid supplementation on redox status, physiological and biochemical parameters in G6PD deficient individuals after acute exercise.
- Trial name
- NCT02937363
- Testing
- Alpha-lipoic acid
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- University of Thessaly
Hemolytic Disorders, Gallstones
The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders
It is well established that hemolytic diseases predispose patients to the development of pigment gallstones. Gallstones are noted in at least 5% of children under the age of 10 years, increasing to 40-50% in the second to fifth…
- Trial name
- NCT02472509
- Testing
- Ursodeoxycholic Acid
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Shaare Zedek Medical Center
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Malaria, Vivax, G6PD Deficiency
Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
This is an observational study carried out in Brazil in patients with P. vivax malaria. The study will be carried out in the municipalities of Manaus (state of Amazonas) and Porto Velho (state of Rondônia).
- Trial name
- Trust (NCT05096702)
- Testing
- Tafenoquine, Primaquine
- Where
- 41 sites in Brazil
- Volunteers
- 16,000 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Glucose-6-Phosphate Dehydrogenase Deficiency
Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is prevalent and add a burden on families in Egypt and Middle East due to lifelong diet restriction, non-fava beans diet is main food for most families in the region and parents…
- Trial name
- NCT02498340
- Testing
- non- fava beans
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Malaria, Vivax
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
This is a prospective, open-label, multicenter, non-comparative, single arm study of pediatric subjects with Plasmodium vivax (P. vivax) malaria, aged 6 months to <16 years of age. A total of 60 subjects will be enrolled.
- Trial name
- NCT02563496
- Testing
- Tafenoquine, Chloroquine
- Where
- 4 sites in Colombia, Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Malaria
Malaria Studies in Cambodia
This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following…
- Trial name
- NCT00663546
- Where
- 3 sites in Cambodia
- Volunteers
- 1,978 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease.
- Trial name
- SCOPE (NCT05879224)
- Testing
- Revised case management package
- Where
- 6 sites in Indonesia
- Volunteers
- 2,999 people
- Sponsor
- Menzies School of Health Research
G6PD, G6PD Deficiency
Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
A prospective clinical study to compare the clinical performance of the FINDER™ Instrument and the G6PD assay to an FDA cleared instrument/reagent combination in adult and neonate populations.
- Trial name
- NCT04146246
- Testing
- G6PD assay
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Baebies, Inc.
Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in…
- Conditions
- Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
- Trial name
- NCT00004381
- Testing
- tin mesoporphyrin
- Where
- 2 sites in United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)